| Description | AZD8848 is a selective antedrug agonist of toll-like receptor 7 (TLR7). It is developed for the research of asthma and allergic rhinitis. |
| In vitro | AZD8848 is able to inhibit Th2 responses in vitro. AZD8848 shows good activity against TLR7, with cellular pEC50s of 7.0 and 6.6 for human TLR7 and rat TLR7, respectively. AZD8848 has no activity against human TLR8 or against any of the other human TLRs. AZD8848 has an EC50 of 4 nM in the induction of IFNα from human PBMCs and an IC50 of 0.2-1.0 nM for the inhibition of IL-5, irrespective of whether the T cells have been polyclonally stimulated with PHA or via antigen presentation. |
| In vivo | AZD8848 (0.3 mg/kg; Intratracheal) suppresses the ovalbumin (OVA) challenge in the rat allergy model. AZD8848 (0.1-1 mg/kg; intratracheal) has good pharmacokinetics in the Brown Norway rat. |
| molecular weight | 569.7 |
| Molecular formula | C29H43N7O5 |
| CAS | 866269-28-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Delaney S, et al. Tolerability in man following inhalation dosing of the selective TLR7 agonist, AZD8848. BMJ Open Respir Res. 2016 Feb 23;3(1):e000113. |